NOVALIQ GmbH | MedPath

Eyenovia and Betaliq Plan Reverse Merger to Create Innovative Ophthalmic Technology Company

2 months ago

• Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity. • The merger would combine Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform, potentially creating a revolutionary approach to topical eye medication administration. • If completed, the combined company would continue marketing Eyenovia's FDA-approved products while developing new treatment options for glaucoma and other ocular diseases through established partnerships.

Perfluorohexyloctane Shows Promise for Dry Eye Disease in Pooled Phase 3 Analysis

8 months ago

• Pooled data from two Phase 3 trials (GOBI and MOJAVE) demonstrate that perfluorohexyloctane ophthalmic solution significantly improves signs and symptoms of dry eye disease (DED). • The analysis included patients with DED associated with Meibomian gland dysfunction (MGD), showing efficacy across various demographic and disease severity subgroups. • Perfluorohexyloctane led to greater reductions in total corneal fluorescein staining (tCFS) and eye dryness visual analog scale (VAS) scores compared to hypotonic saline control. • The most common adverse event was mild, transient blurred vision, suggesting perfluorohexyloctane is generally well-tolerated for treating DED.